Chicago Partners Investment Group LLC Trims Position in Edwards Lifesciences Co. (NYSE:EW)

Chicago Partners Investment Group LLC cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,415 shares of the medical research company’s stock after selling 307 shares during the period. Chicago Partners Investment Group LLC’s holdings in Edwards Lifesciences were worth $320,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock worth $3,577,163,000 after purchasing an additional 325,808 shares during the period. Brown Advisory Inc. grew its stake in Edwards Lifesciences by 20.1% in the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after purchasing an additional 3,048,274 shares during the period. Wellington Management Group LLP grew its stake in Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after purchasing an additional 1,390,427 shares during the period. Norges Bank purchased a new stake in Edwards Lifesciences in the fourth quarter worth $648,540,000. Finally, Northern Trust Corp grew its stake in shares of Edwards Lifesciences by 3.9% in the third quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company’s stock worth $440,446,000 after acquiring an additional 241,347 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 0.5 %

EW stock opened at $86.87 on Tuesday. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The business’s 50-day moving average is $87.65 and its two-hundred day moving average is $84.07. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The company has a market cap of $52.35 billion, a price-to-earnings ratio of 37.44, a P/E/G ratio of 3.19 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Insiders have sold 127,104 shares of company stock valued at $11,267,464 over the last quarter. 1.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Oppenheimer increased their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Barclays increased their target price on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 7th. The Goldman Sachs Group assumed coverage on Edwards Lifesciences in a research note on Thursday, May 30th. They issued a “buy” rating and a $107.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $86.00 to $103.00 in a research note on Tuesday, May 14th. Finally, StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.